Allworth Financial LP Sells 23,421 Shares of Edwards Lifesciences Corporation $EW

Allworth Financial LP cut its position in Edwards Lifesciences Corporation (NYSE:EW) by 58.5% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 16,600 shares of the medical research company’s stock after selling 23,421 shares during the period. Allworth Financial LP’s holdings in Edwards Lifesciences were worth $1,502,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the business. BlackRock Inc. bought a new stake in Edwards Lifesciences in the 2nd quarter valued at approximately $5,318,092,000. Varma Mutual Pension Insurance Co bought a new stake in Edwards Lifesciences during the 2nd quarter worth about $11,168,000. Norges Bank acquired a new position in shares of Edwards Lifesciences during the 4th quarter worth about $803,686,000. Conway Capital Management Inc. acquired a new position in shares of Edwards Lifesciences during the 2nd quarter worth about $954,000. Finally, TD Asset Management Inc boosted its holdings in shares of Edwards Lifesciences by 6.4% in the 4th quarter. TD Asset Management Inc now owns 778,129 shares of the medical research company’s stock valued at $66,335,000 after buying an additional 47,051 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel Lippis sold 619 shares of the business’s stock in a transaction that occurred on Friday, September 11th. The shares were sold at an average price of $87.51, for a total value of $54,168.69. Following the completion of the transaction, the vice president owned 40,034 shares of the company’s stock, valued at $3,503,375.34. The trade was a 1.52% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 544 shares of the stock in a transaction on Monday, August 31st. The stock was sold at an average price of $91.06, for a total transaction of $49,536.64. Following the completion of the transaction, the senior vice president directly owned 14,868 shares in the company, valued at $1,353,880.08. The trade was a 3.53% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 5,664 shares of company stock worth $511,918 over the last three months. 0.31% of the stock is owned by insiders.

Edwards Lifesciences Stock Performance

Shares of Edwards Lifesciences stock opened at $84.54 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.52 and a quick ratio of 3.77. Edwards Lifesciences Corporation has a one year low of $72.30 and a one year high of $96.29. The firm has a market capitalization of $48.68 billion, a price-to-earnings ratio of 48.59, a PEG ratio of 2.28 and a beta of 0.85. The business has a 50-day simple moving average of $89.16 and a 200 day simple moving average of $85.79.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.04. The business had revenue of $1.74 billion for the quarter, compared to analysts’ expectations of $1.70 billion. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The business’s revenue was up 13.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.67 earnings per share. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, research analysts anticipate that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Key Stories Impacting Edwards Lifesciences

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: CMS expands TAVR coverage: The Centers for Medicare and Medicaid Services will extend Medicare coverage to certain patients with severe aortic stenosis who do not yet have symptoms. The broader eligible patient population could increase demand for Edwards’ TAVR valves and procedures, a particularly important growth opportunity for the company. CMS expands TAVR Medicare coverage to asymptomatic patients
• Positive Sentiment: Company welcomes the policy: Edwards said the national coverage determination should improve patient access to TAVR while reinforcing the role of multidisciplinary Heart Teams. The company also reaffirmed its 2026 financial guidance following the decision, suggesting no immediate deterioration in its outlook. Edwards Lifesciences Reaffirms 2026 Guidance Following Medicare TAVR Decision
• Positive Sentiment: Analysts remain bullish: Citi initiated or reiterated a Buy view, while BTIG reaffirmed its Buy rating with a $110 price target. William Blair also maintained a Buy rating, citing the expanded TAVR coverage and inclusion of asymptomatic patients. These targets imply substantial potential upside from recent trading levels. Analyst Buy Rating on Edwards Lifesciences
• Neutral Sentiment: Why the stock may still be under pressure: The reports identify no new company-specific negative catalyst. Investors may be waiting for evidence that the CMS change translates into procedure volumes and revenue, while Edwards’ relatively elevated valuation—about 49 times earnings—could make the shares sensitive to profit-taking or broader market weakness.

Analyst Upgrades and Downgrades

EW has been the subject of several recent analyst reports. BTIG Research reiterated a “buy” rating and issued a $110.00 target price on shares of Edwards Lifesciences in a research note on Friday. Weiss Ratings restated a “hold (c)” rating on shares of Edwards Lifesciences in a report on Friday, July 17th. Citigroup increased their target price on Edwards Lifesciences from $101.00 to $110.00 and gave the stock a “buy” rating in a research note on Wednesday, July 8th. TD Cowen reissued a “buy” rating on shares of Edwards Lifesciences in a report on Tuesday, July 21st. Finally, Wall Street Zen upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating in a research note on Saturday. Seventeen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $100.27.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation (NYSE:EW) is a medical technology company focused on therapies for structural heart disease. Its products are designed to treat conditions affecting the heart valves and related cardiovascular structures, helping patients with diseases such as aortic stenosis, mitral regurgitation and tricuspid valve disorders.

The company’s portfolio includes transcatheter aortic valve replacement systems, including its SAPIEN platform, as well as transcatheter mitral and tricuspid therapies and surgical heart valve products.